At 12 hours after injection, which is the time point before DC migration to TDLNs or MEDI9197-mediated tumor apoptosis occurred, the mcMEDI group showed significantly increased frequencies of activated DCs (CD86+) and T cell subpopulations (CD69+) in the tumor tissue (Figure 3H). The gene discussed is CD86; the disease is neoplasm.